DBV Soars As Path For Peanut Allergy Patch Approval Clears
Positive FDA Feedback After Earlier Rejection
Executive Summary
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.
You may also be interested in...
Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire
Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.
Aimmune's Peanut Immunotherapy Palforzia Gets CHMP Backing
Palforzia will almost certainly be the first treatment to get the green light for peanut allergy in Europe and its new owner will be hoping for a more successful launch than has been seen in the US.
Nestle, Bullish On Palforzia, To Buy Remainder Of Aimmune
Since Palforzia likely will be the only peanut allergy drug on market for some time, Nestle announces it will pay about $2.6bn to acquire the 80% of Aimmune it doesn’t own.